Daiichi Sankyo and Tempus AI are collaborating on the medical growth of ADC
Daiichi Sankyo has entered right into a strategic partnership with Tempus AI to speed up the medical growth and differentiation of an antibody drug conjugate (ADC) program in oncology.
Daiichi Sankyo will use Tempus’ core fashions similar to PRISM2, which integrates pathology photographs and medical knowledge to generate diagnostic and predictive insights.
Uncover B2B advertising and marketing that delivers
Mix enterprise intelligence and editorial excellence to succeed in engaged professionals throughout 36 main media platforms.
Extra info
The partnership will mix Daiichi Sankyo’s medical trial and preclinical analysis knowledge with Tempus’ real-world knowledge, with the goal of figuring out new biomarker discovery alternatives and enhancing affected person stratification.
Each firms will work collectively to develop proof-of-concept AI fashions to optimize affected person choice and improve the prospect of success for a brand new ADC.
The collaboration will deploy these AI fashions in Tempus’ oncology database. This method is anticipated to generate detailed response maps, permitting correct affected person stratification and facilitating benchmarking of potential management arms for upcoming medical trials.
Ryan Fukushima, CEO of Tempus Information and Apps, stated: “Our collaboration with Daiichi Sankyo marks a brand new chapter in how multimodal AI and real-world knowledge might be utilized to advance the event of ADCs.
“Our multimodal foundational fashions search to radically speed up and enhance our capability to uncover unmet affected person wants and determine sufferers most definitely to learn from new therapies.
“Making use of AI to medical growth is now not nearly effectivity; main firms like Daiichi Sankyo are utilizing these fashions to enhance the design of extra focused, impactful medical trials.”
Tempus focuses on advancing precision medication via AI in healthcare. The corporate supplies physicians with AI-powered options for personalised affected person care, whereas supporting the invention, growth and supply of therapies.
In Might 2025, Boehringer Ingelheim entered right into a multi-year partnership with Tempus AI to advance its most cancers remedy pipeline.
The collaboration builds on earlier joint efforts, utilizing AI and knowledge to drive analysis and growth of therapies.
